INTRODUCTION
============

Cerebral infarction (or ischaemic stroke), resulting from a blockage in the blood vessels supplying blood to the brain, or leakage outside the vessel walls, is the leading cause of acquired disability in adults and the second leading cause of dementia \[[@B1]\]. It constitutes the majority of cases of cerebrovascular accidents, and can be atherothrombotic or embolic \[[@B2]\]. According to the Oxford Community Stroke Project classification, cerebral infarction is classified as total anterior circulation infarct, partial anterior circulation infarct, lacunar infarct or posterior circulation infarct \[[@B3]\]. The incidence of cerebral infarction ranged from 210 to 600 per 100000 inhabitants per year according to the geographical difference \[[@B4],[@B5]\]. Approximate 20% mortality is occurred at 1 month after the first stoke \[[@B5]\]. The risk factors are age, gender, tobacco smoking, hypertension, dyslipidaemia, diabetes and atrial fibrillation \[[@B6],[@B7]\]. Increasing number of traditional risk factors was shown to be associated with long-term mortality in patients with cerebral infarction \[[@B8]\]. The symptoms of cerebral infarction are determined by the parts of the brain affected, and the pathology and pathophysiology of this disease are still not well understood \[[@B9]\]. Although many improvements such as surgical evacuation and thrombolytic drugs have been made for patients with cerebral infarction during the last decades, there is no specific treatment due to the severity of bleeding \[[@B10]\]. Preventing cerebral infarctions will be important in reducing the high morbidity and mortality rate \[[@B11]\]. Therefore, it is urgent to identify some important biomarkers to predict this disease and guide the treatment at its early onset.

Cerebral infarction is a complex multifactorial polygenic disease. It is well known that inflammation response affects brain tissue after a stroke, and cells and elements of the immune system are involved in all stages of ischaemic cascade \[[@B12]\]. Interleukins (ILs), a multifunctional group of immunomodulators that primarily mediate the leucocyte cross-talk, is critical to mounting any successful inflammation and immune responses \[[@B13]\]. There are 38 ILs so far, and they mainly regulate the immune cell proliferation, growth, differentiation, survival, activation and functions \[[@B14]\]. In addition, ILs are known to be involved in the pathogenesis of human inflammatory and autoimmune diseases \[[@B15],[@B16]\]. Studies have shown that ILs are associated with atherosclerosis \[[@B17]\], and play an important role in cardiovascular disease \[[@B18]--[@B20]\]. ILs may be major players in the development and progression of cerebral infarction, and the detection of serum ILs might be helpful to assess the severity, therapeutic efficacy and prognosis of patients with cerebral infarction. The increasing of serum IL-6 levels may be related with the occurrence and development of acute cerebral infarction \[[@B21]\]. The lower serum IL-10 concentration was significantly associated with an increased likelihood of cerebral infarction \[[@B22],[@B23]\]. The serum level of IL-18 was significantly elevated in the patients with acute cerebral infarction, and correlated with the volumes of infarction and the clinical neurologic impairment degree scores \[[@B24]\]. IL-33 was shown to be involved in the pathogenesis and/or progression of acute cerebral infarction \[[@B25]\]. Moreover, some specific ILs such as IL-6 might be an independently predictive biomarker for future mortality in the elderly after an ischaemic stroke \[[@B26]\].

Genetic polymorphisms of ILs may affect local serum levels of the proteins and reflect lifelong inflammation status. Recent data suggest that single nucleotide polymorphisms (SNPs) in ILs may contribute to modulating the effects of inflammatory cytokines on cerebral infarction \[[@B27]\]. Although many studies have identified the role of ILs polymorphisms in cerebral infarction risk, the results still remain inconclusive. For example, Rezk et al. \[[@B28]\] inferred that IL-1β −511C/T polymorphism might be associated with more severe functional and neurological impairments in patients with ischaemic stroke, whereas Zhang et al. \[[@B29]\] found no significant association between the IL-1β −511 C/T variant and ischaemic stroke. Therefore, we conducted this meta-analysis to review all the published articles on this issue and reevaluate the relationship between polymorphisms of ILs in cerebral infarction susceptibility to obtain a relatively reliable result.

MATERIALS AND METHODS
=====================

Literature search strategy
--------------------------

We performed a comprehensive literature search in the electronic databases of the Web of Science, PubMed, Embase and the Chinese Biomedical Database to retrieve relevant articles published between January 2000 and December 2015. The following MeSH terms: 'cerebral infarction or brain infarction or cerebral ischaemic stroke', 'interleukin or IL or cytokine', and 'polymorphism or variant or mutation' as well as their combinations were used as the searching keywords in conjunction with a highly sensitive search strategy. The references of retrieved articles were manually searched to obtain more related resources. Our study only focused on articles written in English and Chinese. When the same authors or laboratories published more than one articles in the same subjects, only the most recent full-text article was included.

Inclusion and exclusion criteria
--------------------------------

Eligible studies had to meet the following criteria: (1) case-control study evaluating the correlation of IL genetic polymorphisms in the pathogenesis of cerebral infarction; (2) the patients should be diagnosed by neuroimaging evidence with both CT and MRI, and meet the diagnostic criteria for cerebral infarction according to the World Health Organization\'s diagnostic criteria \[[@B30]\]; (3) the controls should be age-, sex-, ethnic-matched participants without other cardiovascular and cerebrovascular diseases and (4) the genotype information was available to be extracted, and the result was presented in odds ratio (OR) with its 95% confidence intervals (CI). The exclusion criteria were: (1) review reports or conference papers; (2) without control group; (3) with duplicated date and (4) studies not conducted in humans.

Data extraction
---------------

According to the PRISMA guidelines, two of our authors assessed the quality of relevant articles independently. They should reach a final consensus on each item, and any disagreement was solved by discussed with the third author. The following information was extracted: the first author\'s name, published year, country, ethnicity, mean age, sample size, genotype frequencies, genotyping method and Hardy--Weinberg equilibrium (HWE) in controls.

Statistical analysis
--------------------

The relationship between IL genetic polymorphisms and cerebral infarction susceptibility was measured by the pooled OR and 95% CI. The *Z* test was used to estimate the statistical significance of pooled ORs (*P*-value less than 0.05 were considered statistically significant). For each genetic polymorphism, the allelic model, homologous model, heterogeneous model, dominant model and recessive model were calculated. Between-study heterogeneity was evaluated by the *Q*-statistic test and the *I*^2^ test. If the effect was homologous (the *Q*-test showed a *P* \> 0.05 and *I*^2^ test exhibited \<50%), the fixed-effect model was employed; otherwise, the random-effect model was used. All the statistical analysis was performed using the RevMan statistical software (version 5.3, the Cochrane Collaboration, Oxford, England).

RESULTS
=======

Study characteristics
---------------------

After applying the inclusion and exclusion criteria, we totally screened out 55 related articles, containing four genes (IL-1, IL-6, IL-10 and IL-18). [Figure 1](#F1){ref-type="fig"} presented the flow diagram of the selection of studies.

![Flow chart of selection process in this meta-analysis](bsr036e404fig1){#F1}

For IL-1, 17 articles contained three SNPs (IL-1α −899C/T, IL-1β −511C/T and IL-1β +3953C/T). Ten of them were conducted in Asian \[[@B29],[@B31]--[@B39]\], six in Caucasian \[[@B40]--[@B45]\] and one in African \[[@B28]\]. All the genotype frequencies in controls followed the HWE.

For IL-6, 22 articles were included, containing two SNPs (−174G/C and −572C/G). Twelve (eight were written in Chinese \[[@B46]--[@B53]\] and four in English \[[@B54]--[@B57]\]) were conducted in Asian and 10 in Caucasian \[[@B40],[@B58]--[@B66]\]. All the genotype frequencies in controls except the studies of Song et al., Li et al., Sun et al. and Tuttolomondo et al. were conformed to the HWE.

For IL-10, two polymorphisms (−819C/T and −1082A/G) from 10 articles (two were written in Chinese \[[@B67],[@B68]\] and eight in English \[[@B61],[@B69]--[@B75]\]) were included. Seven studies were conducted in Asians and three in Caucasians. The genotype distributions in all controls were consistent with HWE except the studies conducted by Zhang et al. and Marousi et al.

For IL-18, 8 articles (three in English \[[@B76]--[@B78]\] and five in Chinese \[[@B79]--[@B83]\]) contained 2 polymorphisms (−607C/A and −137G/C). All of them were conducted in Chinese population. The genotype distributions in all controls were consistent with HWE.

[Table 1](#T1){ref-type="table"} listed the detailed characteristics of included studies. [Table 2](#T2){ref-type="table"} exhibited the distribution information of genotypes in cerebral infarction cases and matched-controls.

###### Main characteristics of included studies in this meta-analysis

--, Not available; ARMS-PCR, amplification refractory mutation system PCR methods; PCR-RFLP, PCR-restriction fragment length polymorphism; PCR-SSP, PCR-sequence specific primer; RT-PCR, reverse transcription-PCR.

                                                Mean age         Sample size                   
  ---------------- ------ --------- ----------- ---------------- --------------- ------ ------ ------------
  **IL-1**                                                                                     
  Seripa D         2003   Italy     Caucasian   65.8±10.4        63.7±14.0       101    110    PCR-RFLP
  Um JY            2003   Korea     Asian       61.0±14.5        62.2±9.8        363    640    PCR-RFLP
  Blading J        2004   Ireland   Caucasian   69 (35--99)      37.1 (18--65)   105    389    PCR-RFLP
  Dziedzic T       2004   Poland    Caucasian   65.2±14.7        64.8±14.8       183    180    PCR-RFLP
  lacoviello L     2005   Italy     Caucasian   35±7             35±8            134    134    PCR-RFLP
  Rubattu S        2005   Italy     Caucasian   35.95±8.12       34.7±6.9        115    180    PCR-RFLP
  Wei YS           2005   China     Asian       66.9±9.5         65.7±10.2       155    170    PCR-RFLP
  Lai JT           2006   China     Asian       56.85±13.10      27.16±5.25      112    95     PCR-RFLP
  Zhang GZ         2006   China     Asian       56±8             55±6            110    110    PCR-RFLP
  Banerjee I       2008   India     Asian       58.6±14.2        57.4±8.8        112    212    PCR-RFLP
  Zee RYL          2008   USA       Caucasian   62.1±0.5         61.7±0.5        258    258    PCR-RFLP
  Dong RF          2009   China     Asian       60.31±10.51      58.77±10.83     82     82     PCR-RFLP
  Li N             2010   China     Asian       63.88±7.36       62.87±7.57      371    371    PCR-RFLP
  Ma XL            2012   China     Asian       46--75           44--70          65     130    PCR-RFLP
  Zhao N           2012   China     Asian       59.2±10.71       62.32±10.68     1124   1163   PCR-RFLP
  Zhang Z          2013   China     Asian       66.6±8.4         66.1±5.2        440    486    PCR-RFLP
  Rezk NA          2015   Egypt     African     61.2±11.6        62.8±10.8       176    320    PCR-RFLP
  **IL-6**                                                                                     
  Revilla M        2002   Spain     Caucasian   64.9±9.5         64.8±9.1        82     82     PCR-RFLP
  Pola R           2003   Italy     Caucasian   76.8±8.4         76.2±7.1        119    133    PCR-RFLP
  Blading J        2004   Ireland   Caucasian   69 (35--99)      37.1 (18--65)   105    389    PCR-RFLP
  Flex A           2004   Italy     Caucasian   76.2±9.4         76.1±6.8        237    223    PCR-RFLP
  Wei YS           2004   China     Asian       62.7±10.3        60.9±9.1        160    175    PCR-RFLP
  Chamorro A       2005   Spain     Caucasian   67.0±10          64.0±10         273    105    PCR-RFLP
  Song XJ          2005   China     Asian       68.23±9.58       66.08±8.62      66     98     PCR-RFLP
  Lalouschek W     2006   Austria   Caucasian   53 (49--57)      49 (43--56)     404    415    PCR-RFLP
  Li HJ            2006   China     Asian       64.92±11.16      63.91±11.96     112    105    PCR-RFLP
  Yamada Y         2006   Japan     Asian       67.2±11.1        60.6±11.3       636    2010   PCR-SSP
  Banerjee I       2008   India     Asian       58.6±14.2        57.4±8.8        112    212    PCR-RFLP
  Liang J          2009   China     Asian       59.9±9.8         61.5±11.1       199    196    PCR-RFLP
  Sun Y            2009   China     Asian       59.12±12.13      58.71±11.83     92     110    PCR-RFLP
  Liu DF           2010   China     Asian       61.5±13.5        58.5±9.5        157    163    PCR-RFLP
  Tong YQ          2010   China     Asian       61.52±9.68       60.61±9.11      748    748    Sequencing
  Pan Y            2011   China     Asian       62.6±10.2        61.4 ±10.5      106    92     PCR-RFLP
  Xiao H           2011   China     Asian       59.9±9.8         61.5 ±11.1      200    196    PCR-RFLP
  Balcerzyk A      2012   Poland    Caucasian   8.75 (0.5--18)   7.5 (0.2--18)   80     138    PCR-RFLP
  Chakraborty B    2012   India     Asian       54.0±10.9        52.5 ±9.8       100    120    PCR-RFLP
  Tuttolomondo A   2012   Italy     Caucasian   71.9±9.75        71.4 ±7.45      96     48     PCR-RFLP
  Xuan Y           2014   China     Asian       45.4±9.5         44.8±10.1       430    461    PCR-RFLP
  Bazina A         2015   Croatia   Caucasian   54 (51--57)      55 (50--61)     114    187    RT-PCR
  Ozkan A          2015   Turkey    Caucasian   63.57±15.3       62.29±12.6      42     48     RT-PCR
  **IL-10**                                                                                    
  Zhang GZ         2007   China     Asian       55±9             35±5            204    131    PCR-RFLP
  Munshi A         2010   India     Asian       49.3±17.34       47.01±16.78     480    470    ARMSPCR
  Jin L            2011   China     Asian       --               --              189    92     PCR-RFLP
  Marousi S        2011   Greece    Caucasian   68 (58--76)      69 (58--77)     145    145    RT-PCR
  Sultana S        2011   India     Asian       53.72±11.11      54.06±10.98     238    226    ARMS PCR
  Tuttolomondo A   2012   Italy     Caucasian   71.9±9.75        71.4±7.45       96     48     PCR-RFLP
  He W             2015   China     Asian       --               --              260    260    PCR-RFLP
  Jiang XH         2015   China     Asian       66.11±10.54      65.43±11.62     181    115    PCR-RFLP
  Kumar P          2015   India     Asian       50.97±12.70      52.83±12.59     250    250    PCR-RFLP
  Ozkan A          2015   Turkey    Caucasian   63.57±15.3       62.29±12.6      42     48     RT-PCR
  **IL-18**                                                                                    
  Zhang N          2010   China     Asian       68.3±11.4        67.5±6.6        423    384    PCR-SSP
  Li XQ            2011   China     Asian       62 (47--76)      59 (46--75)     98     100    PCR-SSP
  Wang YJ          2011   China     Asian       64.2±13.1        63.9±12.9       218    218    PCR-SSP
  Ren DL           2012   China     Asian       66.06±7.96       64.52±6.57      193    120    PCR-SSP
  Lu JX            2013   China     Asian       65.7±8.8         64.6±9.9        386    364    PCR-RFLP
  Wei GY           2013   China     Asian       58.5±12.1        59.6±12.8       153    114    PCR-RFLP
  Dai XL           2014   China     Asian       63.88±7.36       62.87±7.57      371    371    PCR-RFLP
  Shi JH           2015   China     Asian       62.4±9.3         61.8±10.6       322    322    PCR-RFLP

###### Information of genotype distribution in cerebral infarction cases and controls among included studies in this meta-analysis

  First author                       Cases                       Controls                 HWE
  ---------------- ----- ----- ----- ------- ------ ------ ----- ---------- ------ ------ -------
  **IL-1**                                                                                
  IL-1α −899C/T    CC    CT    TT    C       T      CC     CT    TT         C      T      
  Um JY            292   68    3     652     74     554    81    5          1189   91     0.57
  Wei YS           115   37    3     267     43     146    23    1          315    25     0.99
  Zhang GZ         84    23    3     191     29     97     13    0          207    13     0.80
  Banerjee I       38    62    12    138     86     104    89    19         297    127    0.99
  Dong RF          46    26    10    118     46     68     12    2          148    16     0.31
  Li N             121   207   43    449     293    154    183   34         491    251    0.14
  Zhao N           11    189   924   211     2037   10     220   933        240    2086   0.75
  Zhang Z          145   232   63    522     335    200    237   49         637    358    0.22
  Rezk NA          48    84    44    180     172    180    118   22         478    162    0.91
  IL-1β −511C/T    CC    CT    TT    C       T      CC     CT    TT         C      T      
  Seripa D         41    47    13    129     73     39     58    13         136    84     0.47
  Dziedzic T       94    69    20    257     109    87     79    14         253    107    0.79
  lacoviello L     66    59    9     191     77     52     61    21         165    103    0.91
  Rubattu S        47    51    17    145     85     79     83    18         241    119    0.85
  Lai JT           25    55    32    105     119    30     46    19         106    84     0.98
  Zhang GZ         28    51    31    107     113    30     52    28         112    108    0.85
  Zee RYL          113   123   22    349     167    111    120   27         342    174    0.81
  Dong RF          52    23    7     127     37     46     26    10         118    46     0.15
  Li N             93    170   108   356     386    101    178   92         380    362    0.74
  Ma XL            42    17    6     101     29     87     39    4          213    47     0.99
  Zhao N           298   561   265   1157    1091   323    583   257        1229   1097   0.98
  Zhang Z          119   226   95    464     416    108    261   117        477    495    0.26
  Rezk NA          53    87    36    193     159    206    101   13         513    127    0.99
  IL-1β+3953C/T    CC    CT    TT    C       T      CC     CT    TT         C      T      
  Um JY            332   30    1     694     32     593    46    1          1232   48     0.99
  Blading J        66    35    4     167     43     240    125   24         605    173    0.38
  Zhang GZ         97    13    0     207     13     106    4     0          216    4      0.98
  Dong RF          52    24    6     128     36     57     20    5          134    30     0.25
  Ma XL            34    19    12    87      43     82     42    8          206    58     0.71
  **IL-6**                                                                                
  −174G/C          GG    GC    CC    G       C      GG     GC    CC         G      C      
  Revilla M        37    39    6     113     51     27     40    15         94     70     0.99
  Pola R           56    48    15    160     78     28     58    47         114    152    0.45
  Blading J        33    60    12    126     84     123    198   68         444    334    0.75
  Flex A           100   115   22    315     159    66     99    68         231    235    0.07
  Chamorro A       104   134   35    342     204    46     50    9          142    68     0.67
  Song XJ          54    7     5     115     17     93     4     1          190    6      0.008
  Lalouschek W     143   187   74    473     335    156    192   67         504    326    0.83
  Li HJ            39    24    49    102     122    55     29    21         139    71     0.000
  Banerjee I       77    35    0     189     35     156    52    4          364    60     0.99
  Sun Y            32    20    40    84      100    59     28    23         146    74     0.000
  Liu DF           138   19    0     295     19     153    10    0          316    10     0.92
  Tong YQ          747   1     0     1495    1      743    5     0          1491   5      0.99
  Balcerzyk A      21    43    16    85      75     40     76    22         156    120    0.37
  Chakraborty B    57    35    8     149     51     73     39    8          185    55     0.68
  Tuttolomondo A   40    46    10    126     66     14     33    1          61     35     0.003
  Xuan Y           205   170   55    580     280    246    171   44         663    259    0.21
  Bazina A         39    53    22    131     97     63     98    26         224    150    0.46
  Ozkan A          4     22    16    30      54     14     21    13         49     47     0.69
  −572C/G          CC    CG    GG    C       G      CC     CG    GG         C      G      
  Wei YS           84    71    5     239     81     116    57    2          289    61     0.22
  Yamada Y         412   199   25    1023    249    1138   760   112        3036   984    0.60
  Liang J          103   89    7     295     103    127    66    3          320    72     0.23
  Liu DF           34    33    3     101     36     51     24    5          126    34     0.65
  Tong YQ          373   326   49    1072    424    424    267   57         1115   381    0.26
  Pan Y            55    44    7     154     58     59     32    1          150    34     0.33
  Xiao H           103   89    7     295     103    127    66    3          320    72     0.22
  Xuan Y           267   127   35    661     197    318    122   21         758    164    0.12
  **IL-10**                                                                               
  −819C/T          CC    CT    TT    C       T      CC     CT    TT         C      T      
  Zhang GZ         28    90    86    146     262    27     48    56         102    160    0.03
  Jin L            12    82    95    106     272    7      37    48         51     133    0.99
  Tuttolomondo A   63    14    19    140     52     26     17    5          69     27     0.69
  He W             43    113   104   199     321    33     111   116        177    343    0.73
  Jiang XH         32    73    76    137     225    18     44    53         80     150    0.24
  −1082A/G         AA    AG    GG    A       G      AA     AG    GG         A      G      
  Zhang GZ         202   2     0     406     2      120    11    0          251    11     0.88
  Munshi A         92    241   147   425     535    63     218   189        344    596    0.99
  Jin L            161   27    1     349     29     78     12    2          168    16     0.23
  Marousi S        47    71    27    165     125    53     71    21         177    113    0.94
  Sultana S        154   44    40    352     124    163    47    16         373    79     0.000
  Tuttolomondo A   58    14    24    130     62     20     17    11         57     39     0.18
  He W             41    124   95    206     314    29     108   123        166    354    0.77
  Jiang XH         153   28    0     334     28     83     32    0          198    32     0.22
  Kumar P          11    77    162   99      401    4      37    209        45     455    0.31
  Ozkan A          11    26    5     48      36     19     18    11         56     40     0.28
  **IL-18**                                                                               
  −607C/A          CC    CA    AA    C       A      CC     CA    AA         C      A      
  Zhang N          122   227   74    471     375    81     207   96         369    399    0.29
  Li XQ            25    55    18    105     91     23     56    21         102    98     0.48
  Ren DL           58    99    36    215     171    17     71    32         105    135    0.08
  Lu JX            116   188   82    420     352    77     195   92         349    379    0.38
  Dai XL           43    207   121   293     449    34     183   154        251    491    0.14
  Shi JH           88    180   54    356     288    68     183   71         319    325    0.05
  −137G/C          GG    GC    CC    G       C      GG     GC    CC         G      C      
  Li XQ            76    19    3     171     25     62     33    5          157    43     0.98
  Wang YJ          174   42    2     390     46     146    66    6          358    78     0.90
  Ren DL           161   29    3     351     35     96     23    1          215    25     0.96
  Wei GY           91    54    8     236     70     85     25    4          195    33     0.48
  Dai XL           108   170   93    386     356    92     178   101        362    380    0.74
  Shi JH           230   81    11    541     103    220    84    18         524    120    0.05

Correlation between ILs polymorphisms and susceptibility to cerebral infarction
-------------------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} showed the summary risk estimates for association between ILs polymorphisms and cerebral infarction.

###### Meta-analysis on the association between ILs polymorphisms and cerebral infarction risk in total population

*N*, number of included studies; Ph, *I*^2^, test of heterogeneity; F, fixed-effect model; R, random-effect model.

                                                    Test of association   Test of heterogeneity                    
  ------------------------ ------------------- ---- --------------------- ----------------------- ---------- ----- ---
  **IL-1** IL-1α −899C/T   T versus C          9    1.69 (1.33, 2.14)     \<0.0001                \<0.0001   82%   R
                           TT versus CC             2.32 (1.34, 3.99)     0.002                   0.0007     70%   R
                           CT versus CC             1.66 (1.44, 1.91)     \<0.00001               0.07       45%   F
                           TT + CT versus CC        1.89 (1.46, 2.44)     \<0.00001               0.003      65%   R
                           TT versus CT + CC        1.76 (1.18, 2.64)     0.006                   0.0009     70%   R
  IL-1β −511C/T            T versus C          13   1.11 (0.91, 1.35)     0.32                    \<0.0001   85%   R
                           TT versus CC             1.27 (0.88, 1.84)     0.21                    \<0.0001   80%   R
                           CT versus CC             1.04 (0.84, 1.29)     0.72                    0.0001     69%   R
                           TT + CT versus CC        1.09 (0.85, 1.40)     0.51                    \<0.0001   80%   R
                           TT versus CT + CC        1.23 (0.93, 1.62)     0.14                    \<0.0001   71%   R
  IL-1β +3953C/T           T versus C          5    1.24 (1.00, 1.54)     0.05                    0.09       50%   F
                           TT versus CC             1.47 (0.83, 2.60)     0.19                    0.12       48%   F
                           CT versus CC             1.21 (0.93, 1.57)     0.16                    0.40       1%    F
                           TT + CT versus CC        1.24 (0.97, 1.60)     0.09                    0.29       20%   F
                           TT versus CT + CC        1.43 (0.82, 2.51)     0.21                    0.11       50%   F
  **IL-6**                                                                                                         
  −174G/C                  C versus G          18   1.12 (0.88, 1.43)     0.37                    \<0.0001   86%   R
                           CC versus GG             1.13 (0.68, 1.88)     0.64                    \<0.0001   85%   R
                           GC versus GG             1.04 (0.92, 1.17)     0.56                    0.02       47%   F
                           CC + GC versus GG        1.09 (0.85, 1.41)     0.48                    \<0.0001   75%   R
                           CC versus GC + GG        1.11 (0.71, 1.72)     0.65                    \<0.0001   83%   R
  −572C/G                  G versus C          8    1.31 (1.03, 1.66)     0.03                    \<0.0001   84%   R
                           GG versus CC             1.48 (0.88, 2.48)     0.14                    0.006      64%   R
                           CG versus CC             1.38 (1.04, 1.83)     0.03                    \<0.0001   82%   R
                           GG + CG versus CC        1.40 (1.05, 1.88)     0.02                    \<0.0001   84%   R
                           GG versus CG + CC        1.28 (0.81, 2.02)     0.29                    0.03       55%   R
  **IL-10**                                                                                                        
  −819C/T                  T versus C          5    0.93 (0.80, 1.09)     0.38                    0.64       0%    F
                           TT versus CC             0.97 (0.71, 1.33)     0.86                    0.34       12%   F
                           CT versus CC             0.91 (0.54, 1.52)     0.71                    0.03       62%   R
                           TT + CT versus CC        0.93 (0.70, 1.22)     0.59                    0.19       35%   F
                           TT versus CT + CC        0.92 (0.75, 1.13)     0.42                    0.56       0%    F
  −1082A/G                 G versus A          10   0.76 (0.57, 1.02)     0.07                    \<0.0001   82%   R
                           GG versus AA             0.78 (0.46, 1.34)     0.37                    0.0003     74%   R
                           AG versus AA             0.76 (0.54, 1.07)     0.12                    0.004      63%   R
                           GG + AG versus AA        0.74 (0.52, 1.05)     0.09                    0.0004     70%   R
                           GG versus AG + AA        0.80 (0.51, 1.24)     0.31                    \<0.0001   80%   R
  **IL-18**                                                                                                        
  −607C/A                  A versus C          6    0.76 (0.69, 0.84)     \<0.00001               0.76       0%    F
                           AA versus CC             0.56 (0.45, 0.68)     \<0.00001               0.68       0%    F
                           CA versus CC             0.71 (0.59, 0.84)     \<0.0001                0.43       0%    F
                           AA + CA versus CC        0.66 (0.55, 0.77)     \<0.00001               0.48       1%    F
                           AA versus CA + CC        0.70 (0.60, 0.82)     \<0.0001                0.93       0%    F
  −137G/C                  C versus G          6    0.83 (0.62, 1.10)     0.20                    0.003      72%   R
                           CC versus GG             0.75 (0.55, 1.03)     0.08                    0.43       0%    F
                           GC versus GG             0.82 (0.57, 1.16)     0.26                    0.005      70%   R
                           CC + GC versus GG        0.81 (0.57, 1.14)     0.23                    0.003      73%   R
                           CC versus GC + GG        0.84 (0.64, 1.11)     0.21                    0.58       0%    F

### IL-1

For IL-1α −899C/T polymorphism, 9 articles included 2933 cerebral infarction patients and 3554 controls. The frequency of T allele was shown to be higher in cases than that in controls (53.5% versus 43.7%), and our result identified that IL-1α −899C/T polymorphism was associated with cerebral infarction risk under each genetic models (T versus C: OR=1.69, 95% CI=1.33--2.14, *P*\<0.0001; TT versus CC: OR=2.32, 95% CI=1.34--3.99, *P*=0.002; CT versus CC: OR=1.66, 95% CI=1.44--1.91, *P*\<0.00001; TT + CT versus CC: OR=1.89, 95% CI=1.46--2.44, *P*\<0.00001; TT versus CT + CC: OR=1.76, 95% CI=1.18--2.64, *P*=0.006) as shown in [Figure 2.](#F2){ref-type="fig"}

![Meta-analysis of the relationship between the IL-1α −899C/T polymorphism and cerebral infarction risk under the allelic model (**A**), homologous model (**B**), heterogeneous model (**C**), dominant model (**D**) and recessive model (**E**).](bsr036e404fig2){#F2}

For IL-1β −511C/T polymorphism, there were 3271 cerebral infarction cases and 3619 controls from 13 articles. We did not detect a significant association between IL-1β −511C/T polymorphism and cerebral infarction susceptibility under any genetic models in the random-effect model ([Table 3](#T3){ref-type="table"}).

For IL-1β +3953C/T polymorphism, 5 articles contained 725 patients and 1353 controls. Our result found that there was no positive relationship between IL-1β +3953C/T polymorphism and cerebral infarction risk in the fixed-effect model as well ([Table 3](#T3){ref-type="table"}).

### IL-6

For IL-6 −174G/C polymorphism, 18 articles contained 3369 patients and 3795 controls. Our result did not find a significant relationship between IL-6 −174G/C polymorphism and cerebral infarction occurrence under any genetic models ([Table 3](#T3){ref-type="table"}). Subgroup analysis by ethnicity showed that this genetic variant was associated with increased the risk to cerebral infarction only in Asians (C versus G: OR=1.65, 95% CI=1.19--2.29, *P*=0.003; CC versus GG: OR=2.18, 95% CI=1.29--3.65, *P*=0.003; GC versus GG: OR=1.26, 95% CI=1.04--1.53, *P*=0.02; CC + GC versus GG: OR=1.45, 95% CI=1.21--1.73, *P*\<0.0001; CC versus GC + GG: OR=2.04, 95% CI=1.22--3.40, *P*=0.007) as shown in [Figure 3.](#F3){ref-type="fig"}

![Forest plot of the relative strength of the association between IL-6 −174G/C polymorphism and cerebral infarction risk in Asians under the allelic model (**A**), homologous model (**B**), heterogeneous model (**C**), dominant model (**D**) and recessive model (**E**).](bsr036e404fig3){#F3}

For IL-6 −572C/G polymorphism, 8 articles contained 2547 patients and 3958 controls. Our result found that IL-6 −572C/G polymorphism was positively correlated with cerebral infarction risk under the allelic model (G versus C: OR=1.31, 95% CI=1.03--1.66, *P*=0.03), heterogeneity model (CG versus CC: OR =1.38, 95% CI=1.04--1.83, *P*=0.03) and dominant model (GG + CG versus CC: OR=1.40, 95% CI=1.05--1.88, *P*=0.02) in the random-effect model as shown in [Figure 4.](#F4){ref-type="fig"}

![Meta-analysis of correlation of IL-6 −572C/G polymorphism in cerebral infarction risk under the allelic model (**A**: G versus **C**), heterogeneity model (**B**: CG versus CC) and dominant model (**C**: GG + CG versus CC) in the random-effect model.](bsr036e404fig4){#F4}

### IL-10

For IL-10 −819C/T mutation, 5 articles included 930 patients and 646 controls. Our result found no significant association between this genetic variant and cerebral infarction risk under any comparison models as shown in [Table 3.](#T3){ref-type="table"}

For IL-10 −1082A/G polymorphism, 2085 cases and 1785 controls from 10 relevant articles were screened out. This SNP was not associated with increased the susceptibility of cerebral infarction under each genetic models as well ([Table 3](#T3){ref-type="table"}). Subgroup analysis by ethnicity showed that IL-10 −1082A/G polymorphism was significantly associated with increased the cerebral infarction risk under the allelic model (OR=0.68, 95% CI=0.46--0.99, *P*=0.04) and heterologous model (OR=0.74, 95% CI=0.60--0.92, *P*=0.006) as shown in [Figure 5.](#F5){ref-type="fig"}

![Forest plot of the association between IL-10 −1082A/G polymorphism and cerebral infarction risk under the allelic model (**A**) and heterologous model (**B**).](bsr036e404fig5){#F5}

### IL-18

For IL-18 −607C/A polymorphism, 6 articles contained 1793 cerebral infarction patients and 1661 healthy controls. No significant heterogeneity was detected, and the fixed-effect model was used. Our result found that the frequency of A allele was a little higher in controls than that in patients (55.0% versus 48.1%), but the A allele of IL-18 −607C/A polymorphism was associated with increased the risk of cerebral infarction (A versus C: OR=0.76, 95% CI=0.69--0.84, *P*\<0.00001). This statistically significant was also observed in other genetic models (AA versus CC: OR=0.56, 95% CI=0.45--0.68, *P*\<0.00001; CA versus CC: OR=0.71, 95% CI=0.59--0.84, *P*\<0.0001; AA + CA versus CC: OR=0.66, 95% CI=0.55--0.77, *P*\<0.00001; AA versus CA + CC: OR=0.70, 95% CI=0.60--0.82, *P*\<0.0001). [Figure 6](#F6){ref-type="fig"} showed the result of IL-18 −607C/A polymorphism in cerebral infarction risk.

![Forest plots for association between IL-18 −607C/A polymorphism and cerebral infarction risk under the allelic model (**A**), homologous model (**B**), heterogeneous model (**C**), dominant model (**D**) and recessive model (**E**).](bsr036e404fig6){#F6}

For IL-18 −137G/C polymorphism, five articles included 1355 cases and 1245 controls. Our result found that IL-18 −137G/C polymorphism was not associated with cerebral infarction risk under any genetic comparison models ([Table 3](#T3){ref-type="table"}).

Sensitivity analysis and publication bias
-----------------------------------------

We successively omitted each single study respectively to confirm whether each included study affect the overall results. Our result found that the pooled ORs were not significantly changed. The funnel plots were used to evaluate the publication bias. All the plots were found to be roughly symmetrical, indicating no publication bias presented as shown in [Figure 7](#F7){ref-type="fig"}. However, visual inspection of funnel plots did not guarantee that publication bias was absolutely absent.

![Funnel plot of IL-1α −899C/T (CT versus CC) and IL-6 −174G/C (GC versus GG) polymorphisms in cerebral infarction.](bsr036e404fig7){#F7}

DISCUSSION
==========

In this meta-analysis, we totally identified 55 relevant articles. Our results found that polymorphisms of IL-1α −899C/T and IL-18 −607C/A (under all the genetic models), and IL-6 −572C/G (under the allelic model, heterogeneity model and dominant model) were associated with increased the risk of cerebral infarction. Other genetic polymorphisms were not related with cerebral infarction susceptibility under any genetic models. Subgroup analysis by ethnicity showed that IL-6 −174G/C polymorphism (under all the five models) and IL-10 −1082A/G polymorphism (under the allelic model and heterologous model) were significantly associated with increased the cerebral infarction risk in Asians. This may be due to the higher frequency of C allele of IL-6 −174G/C and G allele of IL-10 −1082A/G in Asian populations. Our results were consistent with previous meta-analysis conducted by Jin et al. \[[@B84]\] and Yin et al. \[[@B85]\] which showed that IL-10 −1082 A/G polymorphism was associated with ischaemic stroke susceptibility in Asians, not consistent with the results from the studies of Kumar et al. \[[@B86]\] and Jin et al. \[[@B87]\] which showed that IL-6 −174G/C and −572C/G polymorphisms were not be associated with an increased susceptibility to ischaemic stroke, and Ye et al. \[[@B88]\] which inferred that IL-1β −511C/T polymorphism might be moderately associated with increased risk of ischaemic stroke.

Cerebral infarction is a complex vascular and metabolic process leading to neuronal death, and the loss of blood supply results in the death of that area of tissue \[[@B89]\]. The mechanisms for clinical deterioration in patients with ischaemic stroke are not completely understood. Interleukins are a kind of immunomodulating agents. They not only provide communication between immune cells, but also play a role in signalling the brain to produce neurochemical, neuroendocrine, neuroimmune and behavioural changes \[[@B90]\]. Several cytokines are released early after the onset of brain ischaemia, and studies have shown that IL-6 participated in the acute-phase response that follows focal cerebral ischaemia, and its levels on admission are associated with early clinical deterioration \[[@B91]\]. Furthermore, exploring these pathophysiological mechanisms underlying ischaemic tissue damage may direct rational drug design in the therapeutic treatment of stroke \[[@B92]\].

A growing body of evidence has indicated an important role of inflammatory cytokines in the pathogenesis of cerebral lesion following stroke \[[@B93]\]. They are critical to the pathogenesis of tissue damage in cerebral infarction \[[@B92]\]. IL-1 was shown to play a systemic inflammation role in acute brain injury \[[@B94]\]. Elevated IL-4 level in the human serum may be an important factor in cerebral infarction during the acute stage \[[@B95]\]. Increasing the serum IL-6 and IL-8 levels may be related with the occurrence and development of acute cerebral infarction \[[@B96]\]. Elevated IL-8 may contribute to stroke pathophysiology by activating polymorphonuclear leucocyte activation early after ischaemia \[[@B97]\]. IL-18 is involved in stroke-induced inflammation and that initial serum IL-18 levels may be predictive of stroke outcome \[[@B98]\].

Genetic polymorphisms may influence the expression level of ILs, which in turn may be associated with cerebral infarction. Analysis of genetic variation within genes coding for inflammatory mediators can offer some advantage compared with analyses of the plasma protein levels. Olsson et al. \[[@B99]\] showed a relationship between IL-1 receptor antagonist polymorphism and overall ischaemic stroke. Tong et al. \[[@B100]\] found that IL-4 variable number of tandem repeats polymorphism might influence the ischaemic stroke susceptibility in the Chinese Uyghur population. Luo et al. \[[@B101]\] demonstrated that the IL-8+781C/T polymorphism was associated with neurological recovery at the acute stage of atherosclerotic cerebral infarction in the Han Chinese population, and the patients with the CT genotype recovered better than those with other genotypes. Guo et al. \[[@B102]\] identified that genetic variation of rs4742 170 in IL33 is significantly associated with the developing of ischaemic stroke.

Several limitations were presented in this meta-analysis. Firstly, there was significant heterogeneity among included studies, which may affect the precision of outcome. Secondly, most of the included studies were conducted in Asian population, whereas other population should be included in the future analysis. Thirdly, due to lacking the detailed information, we could not perform a precise analysis by adjusting potentially suspected factors such as age, gender, smoking status and environmental factors. Lastly, the interaction of gene--gene and gene--environment should be considered.

In conclusions, our results suggested that polymorphisms of IL-1α −899C/T, IL-6 −572C/G and IL-18 −607C/A were positive correlated with increased the risk of cerebral infarction. Subgroup analysis by ethnicity showed that polymorphisms of IL-6 −174G/C and IL-10 −1082A/G were significantly associated with cerebral infarction risk in Asians. Future analysis with well-designed studies and large sample size are still needed to further investigate the association of polymorphisms in ILs and cerebral infarction.
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